[Effects of triptolide on bortezomib-induced apoptosis in multiple myeloma cells]

Yang Yang1, Hong-Juan Dong, Guang-Xun Gao

  • 1Department of Geriatric Hematology, Chinese PLA General Hospital, Beijing, China.

Insights

Triptolide enhances bortezomib-induced apoptosis in multiple myeloma cells. This combination therapy shows increased efficacy compared to single agents, offering a promising strategy for treating multiple myeloma.

Area of Science:

  • Pharmacology
  • Cancer Biology
  • Cell Death Research

Context:

  • Multiple myeloma (MM) is a hematologic malignancy.
  • Bortezomib is a proteasome inhibitor used in MM treatment.
  • Drug resistance remains a challenge in MM therapy.

Purpose:

  • To investigate the synergistic effect of triptolide and bortezomib on multiple myeloma cells.
  • To evaluate the impact of triptolide on bortezomib-induced apoptosis in NCI-H929 cells.

Summary:

  • Triptolide and bortezomib inhibited proliferation of NCI-H929 cells in a dose-dependent manner.
  • Combination treatment significantly increased the apoptotic rate compared to single-drug treatments.
  • Even at a non-inhibitory concentration, triptolide potentiated bortezomib's apoptotic effect.

Impact:

  • Triptolide can enhance the pro-apoptotic activity of bortezomib in multiple myeloma.
  • This finding suggests a potential therapeutic strategy to improve bortezomib efficacy.
  • Further research may explore triptolide as an adjunct therapy for multiple myeloma.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...